TRANSACTION REPORT · SEC DISCLOSURES
Deal notes
ContextDeal context
This is an ATM facility event. The capacity shown is not cash raised.
Gross proceedsNo cash proceeds
Offering price—
Discount to prior close—
Warrant coverage—
Sales agentH.C. Wainwright & Co.
Transaction overview
01Indaptus Therapeutics, Inc. disclosed an at-the-market program event: facility replaced. Authorized capacity is $100.0M. This event does not record cash proceeds raised.
- Financing type
- ATM
- Announcement date
- —
- SEC disclosure date
- Aug 31, 2026
- Agreement date
- Jun 1, 2022
- Pricing date
- —
- Closing date
- —
- Filing date
- Aug 31, 2026
- Status
- Amended
- Market cap before SEC disclosure
- $132.4M
- Prior closing price
- $1.14
- Raise as % of market cap
- —
Market data · FMP
- Historical market cap
- $132,389,582
- Market date
- Aug 28, 2026
- Closing price
- $1.14
- Latest reported shares outstanding
- 113,242,000
- Latest reported float shares
- 4,024,620
- Share-data date
- Oct 1, 2026
Market cap and closing price are from FMP for the date shown. Shares are FMP’s latest available snapshot, dated separately. Updated Oct 1, 2026.
Financial Modeling Prep ↗Financing terms
02At-the-market program
- Capital event
- Facility replaced
- Authorized capacity
- $100.0M
- Proceeds raised
- Not reported as raised
- Shares sold
- —
- Average sale price
- —
- Relevant period
- Not applicable
- Sales commission
- 3%
Fees & transaction economics
03- Placement agent / underwriting fee
- 3%
- Agent fee amount
- —
- Management fee
- —
- Other offering expenses (estimated)
- —
- Net proceeds (estimated)
- —
- Net proceeds as % of gross
- —
Fee amounts reflect disclosed inputs. Unknown expense components are not assumed to be zero.
Transaction participants
04Investor names: —
Source documents
05SEC filings, exhibits and attributed market data. The report separates disclosed facts, calculated metrics, and unknown terms.
424B5 · Indaptus Therapeutics, Inc.SEC filing · Aug 31, 2026
Open source ↗FMP historical market data · INDPMarket data · Aug 28, 2026
Open source ↗424B5 · Indaptus Therapeutics, Inc.SEC filing · Sep 4, 2026
Open source ↗Filing evidence & original calculations
type
ATM
The Offering Agreement replaces and supersedes in its entirety the original at-the-market offering agreementOriginal source ↗
SEC disclosure date
2026-08-31
As Filed Pursuant to Rule 424(b)(5) Registration No. 333-289573 PROSPECTUS SUPPLEMENT (To Prospectus dated August 20, 20Original source ↗
date Basis
sec_disclosure
As Filed Pursuant to Rule 424(b)(5) Registration No. 333-289573 PROSPECTUS SUPPLEMENT (To Prospectus dated August 20, 20Original source ↗
atm Event
Facility replaced
The Offering Agreement replaces and supersedes in its entirety the original at-the-market offering agreementOriginal source ↗
atm Capacity Basis
Authorized capacity
having an aggregate offering price of up to $100,000,000Original source ↗
agreement Date
2022-06-01
original at-the-market offering agreement we entered into with the Sales Agent on June 1, 2022Original source ↗
status
Amended
The Offering Agreement replaces and supersedes in its entirety the original at-the-market offering agreementOriginal source ↗
market Cap
FMP reported market cap; as of 2026-08-28.
{"provider": "FMP", "symbol": "INDP", "date": "2026-08-28", "marketCap": 132389582}Original source ↗